China’s healthcare industry has emerged as one of the fastest growing sectors in the country. A key driver of this growth is China’s rapidly aging population, which is creating higher demand for healthcare services, pharmaceuticals, and medical innovations. The country’s demographic shift has attracted significant attention from policymakers, resulting in a steady increase in public expenditure on healthcare to address evolving needs.
In 2016, the Chinese government launched its “Healthy China 2030” strategy. This comprehensive initiative aims to improve public health and well-being across the country by 2030 through specific goals, including increasing the average life expectancy, enhancing health service capacity, expanding the health industry, and strengthening the health service system. These efforts reflect a long-term commitment to creating an effective healthcare ecosystem while addressing the demands of an aging population.
One notable outcome of this approach has been a heightened focus on the pharmaceutical sector, medical devices, and healthcare services, which presents significant opportunities for international players. For European companies, these developments are particularly promising, as many have already addressed similar health sector challenges in their respective domestic markets. Their expertise positions them to meet the needs of the Chinese market with innovative and adaptable solutions. While market access challenges persist, such as navigating regulatory complexities and intense local competition, the sector remains highly relevant.
On 19 May, the EU SME Centre is organising, in partnership with the European Union Chamber of Commerce in China and the China-Italy Chamber of Commerce, a workshop with experts of China’s healthcare industry to inform SMEs of the evolution of the sector, its regulatory landscape, as well as emerging opportunities and potential hurdles.
Agenda (CST)
15:30–16:00
Registration at the venue For onsite participants in Shanghai
16:00–16:05
Opening remarks Liam Jia, Team Leader, EU SME Centre
16:05–16:25
Overview of China’s Healthcare Sector Jens Ewert, National Leader Life Science Healthcare Industry, Deloitte
16:25–16:45
Registration Procedures for Medical Devices Hamish King, CEO at Cisema
16:45–17:15
Panel discussion Market Access for European SMEs in the Healthcare Sector
17:15–17:25
Q&A session
17:25–17:30
Closing remarks
Speakers and panellists
Jens Ewert
National Leader Life Science Healthcare Industry, Deloitte
Jens Ewert, a Senior Partner with Deloitte China, has over 30 years of working experience in the professional services. Based in Shanghai since end 2002, he has been a member of Deloitte China Eastern Region Management team since then. Jens is the national leader for Deloitte China Life Science & Health Care Industry, leading a dedicated industry team comprising over 1000+ partners and professionals. He also covers our full range of multidisciplinary services, from consulting, risk & financial & tax advisory and audit & assurance, offering to Multinational Clients in China.
Jens has received the ‘Magnolia Silver Award’ from the Shanghai Government in September 2021, recognizing foreign business leaders for their special and outstanding contribution to the City’s development. He is also a Board member at the EUCCC Shanghai and the National Vice-Chair of the Investment Working group at the EU Chamber in China. Prior to moving to China, he has been working in numerous countries always in professional services, such as France, Hungary, Vietnam and Indonesia. He hold a Master degree from University Paris X Dauphine in Business & Finance and a Diploma of Political Science from Institut d’Etudes Politiques de Paris. He also attended numerous executive programs at IMD and Insead. He is married to Christine and calls France his home.
Hamish King
CEO, Cisema
Hamish King, LLB, RAC is CEO at Cisema, a regulatory and compliance consultancy for China founded in Munich and Beijing in 2002. Cisema is a 100-strong family-owned company providing regulatory and compliance services for China and Hong Kong, including product registration, in-China testing, clinical studies and writing, regulatory communications, local agent, post market surveillance, quality control and audits.
A lawyer by training – admitted in Hong Kong and NSW, Australia – Hamish previously worked with UK Magic Circle Firm Linklaters in Hong Kong, and has over 10 years’ experience in the legal and regulatory fields. He has obtained the RAC and CFA qualifications. Regularly writing articles and speaking on China regulatory pathways and registration points, he currently lives in Hong Kong and specialises in NMPA registrations and compliance.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
